Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in Unresectable Stage III NSCLC
jRCT2080220796Phase 2
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nimotuzumab in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
nimotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080220796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220796.